Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa News Observer.
Press releases published on October 20, 2025
AgroGreen and Partners Pioneer Climate-Resilient Agriculture with CSV-P Launch in Akwa Ibom
CSV-P to strengthen Nigeria’s agribusiness value chain through regenerative farming, data-driven systems, and climate-resilient innovation. UYO, AKWA IBOM , NIGERIA, October 20, 2025 /EINPresswire.com/ -- AgroGreen Dynamics Ltd, in collaboration with …
VR Resources Announces $1.5M Brokered Private Placement Led by Centurion One Capital, Concurrent Share Consolidation, Management Change, and Start-Up of Drill Planning for its New Boston Tungsten-Molybdenum-Copper-Silver porphyry project in Nevada
VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- VR Resources Limited (“VR” or the “Company”, TSXV: VRR) is pleased to announce that it has entered into an agreement with Centurion One Capital Corp. (the “Lead Agent”) as lead agent and sole …
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards. As previously disclosed, …
غرينبيس: سنوات من التحذيرات قابس بحاجة للتحرّك العاجل لتنفيذ القرار الحكومي الصادر في 29 جوان 2017 وإنقاذ حياة المواطنين
غرينبيس الشرق الأوسط وشمال أفريقيا: سنوات من التحذيرات… قابس بحاجة للتحرّك العاجل لتنفيذ القرار الحكومي الصادر في 29 جوان 2017 وإنقاذ حياة المواطنين قابس, TUNISIA, October 20, 2025 /EINPresswire.com/ -- تتابع منظمة غرينبيس الشرق الأوسط وشمال أفريقيا …
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat …
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on October 20, 2025, …
Imperial Reports Mount Polley Production Update for 2025 Third Quarter
VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Imperial Metals Corporation (the “Company” or “Imperial”) (TSX:III) reports quarterly copper and gold production from the 100% owned Mount Polley mine. Imperial’s third quarter production from …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle Pharmaceuticals Ltd. for Phyrago™ (dasatinib) tablets. Phyrago is a kinase inhibitor …
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
New York, NY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the U.S. Food and Drug Administration (FDA) …
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) (“Lexeo”), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced the closing of its previously …
تعلن داراديا عن ورش عمل على الجثث حول إجراءات الألم باستخدام C-Arm وUSG: بمشاركة 35-40 طبيبًا لكل دفعة و150 طبيبًا سنويً
KOLKATA, WEST BENGAL, INDIA, October 20, 2025 /EINPresswire.com/ -- أعلنت داراديا: عيادة الألم عن استمرار سلسلة ورش العمل الكادافيرية للتدخلات العلاجية للألم المعتمدة على التصوير بالتنظير التألقي C-Arm والموجات فوق الصوتية USG، وفق جدول منتظم كل ثلاثة …
IMPALA Appoints Ann Marie Dunne as New Chair, Succeeding Jonathan Taylor
PISCATAWAY, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- IMPALA, a global consortium dedicated to advancing digital and analytics-driven quality in biopharmaceutical development, announced the appointment of Ann Marie Dunne, Global Head of R…
AIM ImmunoTech to Attend the 2025 Maxim Growth Summit
OCALA, Fla., Oct. 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event …
ADARx Pharmaceuticals Announces Clinical Data Presentation at the American Society of Nephrology (ASN) Kidney Week 2025
SAN DIEGO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, announced today that it will present initial Phase 1 clinical data for ADX-038, an …
Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing development of PALI-2108 across fibrostenotic Crohn’s …
Cogent Biosciences Announces FDA Breakthrough Therapy Designation for Bezuclastinib
Detailed results from bezuclastinib’s positive SUMMIT trial evaluating bezuclastinib in patients with NonAdvanced Systemic Mastocytosis planned for presentation at upcoming scientific conference this year NDA submission for bezuclastinib planned by YE 2025 …
Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health …